An Italian chart for cardiovascular risk estimate including high-density lipoprotein-cholesterol

Disease Management and Health Outcomes

Volumn 16, Issue 3, 2008, Pages 183-197

  Menotti, Alessandro ^a   Lanti, Mariapaola ^a  

^a Association for Cardiac Research   (Italy)

Author keywords

Cardiovascular disorders, prevention; Disease prevention; Risk factors

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; FATALITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; ITALY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTOR VARIABLE; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

EID: 44449121423     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200816030-00005     Document Type: Article

References (66)

1. American Heart Association. Coronary risk handbook: estimating the risk of coronary heart disease in daily practice. Dallas (TX): AHA, 1973
2. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-8
3. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
4. Haq IU, Jackson PR, Yeo WW, et al. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346 (8988): 1467-71
5. McCormack JP, Levine M, Rangno RE. Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. CMAJ 1997; 157: 422-8
6. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-503
7. National Heart & Lung Institute. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998; 80 (2): 1-29
8. Cardiac risk assessment V.98.02 [computer program]. PC version. Manchester: University of Manchester, 1998
9. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47
10. Wallis EJ, Ramsay LE, Ul Haq I, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320 (7236): 671-6
11. Thomsen T. Prediction and prevention of cardiovascular diseases: Precard© [thesis]. Copenhagen: University of Copenhagen, 2000
12. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001; 101 (6): 671-9
13. American Heart Association. Health risk awareness [online]. Available from URL: http://www.americanheart.org [Accessed 2007 Sep 1]
14. Procam risk calculator [online]. Available from URL: http://www.CHD- Taskforce.com [Accessed 2007 Sep 1]
15. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105 (3): 310-5
16. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24 (11): 987-1003
17. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ 2000; 320: 709-10
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421
19. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2007 Sep; 14 Suppl. 2: S1-113
20. Keys A, Menotti A, Aravanis C, et al. The Seven Countries Study: 2289 deaths in 15 years. Prev Med 1984; 13: 141-54
21. Menotti A, Lanti M, Puddu PE, et al. Northern vs Southern European population bases in prediction of coronary incidence: a re-analysis and reappraisal of the Seven Countries Study in view of a European coronary risk chart. Heart 2000; 84: 238-44
22. Menotti A, Lanti M, Puddu PE. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21: 365-70
23. Haq IU, Ramsay LE, Yeo WW, et al. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81: 40-6
24. Thomsen TF, McGee D, Davidson M, et al. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002; 31: 817-22
25. de Visser CL, Bilo HJ, Thomsen TF, et al. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med 2003; 253: 553-62
26. Sans S, Fitzgerald AP, Royo D, et al. Calibrating the SCORE cardiovascular risk chart for use in Spain [in Spanish]. Rev Esp Cardiol 2007; 60: 476-85
27. Panagiotakos DB, Fitzgerald AP, Pitsavos C, et al. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J Cardiol 2007; 48: 55-63
28. Manuale del Rischio Coronarico. Per stimare il rischio coronarico nella pratica medica. Udine: Associazione Nazionale Centri per le Malattie Cardiovascolari e CIBA-GEIGY, 1980
29. Menotti A, Lanti M, Agabiti-Rosei E, et al. Riskard 2005: new tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutr Metab Cardiovasc Dis 2005; 15: 426-40
30. Menotti A, Lanti M, Puddu PE, et al. An Italian chart for cardiovascular risk prediction: its scientific basis. Ann Ital Med Int 2001; 16: 240-51
31. Gordon DJ, Probstfield JL, Garrison RJ, et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15
32. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy. Am J Med 1991; 90: 11-6
33. Assman G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J 1998; 19 Suppl. A: A2-A11
34. Sharrett AR, Ballantyne CM, Coady SA, et al. Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol esters, triglycerides, lipoprotein (a), apolipoproteins A-1 and B, HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108-13
35. Carter PH, Gotto A, LaRosa JC, for the Treating to New Targets Investigators, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 301-10
36. Menotti A, Lanti M, Puddu PE. Epidemiologia delle malattie cardiovascolari. Insegnamenti dalle Aree Italiane del Seven Countries Study. Rome: Cardioricerca Ed., 1999: 1-532
37. Menotti A, Lanti M, Puddu PE, et al. First risk functions for prediction of coronary and cardiovascular disease incidence in the Gubbio Population Study. Ital Heart J 2000; 1: 394-9
38. Fazzini PF, Prati PL, Rovelli F, et al. Epidemiology of silent myocardial ischemia in asymptomatic middle-aged men: the ECCIS Project. Am J Cardiol 1993; 72: 1383-8
39. Descovich GC, Aluigi L, Benassi MS, et al. The Brisighella Investigation: results of the observational Study 1972-1980. Minerva Cardioangiol 1985; 33: 565-74
40. The RIFLE Research Group. Presentation of the RIFLE project: risk factors and life expectancy. Eur J Epidemiol 1993; 9: 459-76
41. Averna MR, Barbagallo CM, Montalto G, et al. Progetto di epidemiologia e prevenzione Ventimiglia di Sicilia: dati di popolazione. G Arterioscl 1992; 17: 83-7
42. Muiesan ML, Pasini GF, Salvetti M, et al. Cardiac and vascular structural changes: prevalence and relation to ambulatory blood pressure in a middle-aged general population in Northern Italy: The Vobarno Study. Hypertension 1996; 27: 1046-52
43. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34
44. Ho JE, Paultre F, Mosca L. Women's Pooling Project. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's Pooling Project. Stroke 2003; 34: 2812-6
45. Candido R, Srivastava P, Cooper ME, et al. Diabetes mellitus: a cardiovascular disease. Curr Opin Investig Drugs 2003; 4: 1088-94
46. Lee CD, Folsom AR, Pankow JS, et al. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 2004; 109: 855-60
47. Juutilainen A, Lehto S, Rönnemaa T, et al. Type 2 diabetes as a 'coronary heart disease equivalent': an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28: 2901-7
48. Vongpatanasin W. Cardiovascular morbidity and mortality in high-risk populations: epidemiology and opportunities for risk reduction. J Clin Hypertens (Greenwich) 2007; 9 Suppl. 4: 11-5
49. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136
50. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007 Jan; 30 (1): 162-72
51. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136
52. New Zealand Guidelines. Evidence-based best practice guidelines: assessment and management of cardiovascular risk. Wellington (NZ): New Zealand Guidelines Group, 2003
53. The Royal College of General Practitioners. Effective Clinical Practice Unit. Sheffield/NICE: Clinical guidelines for type 2 diabetes: blood pressure management/lipid management. London: National Institute for Clinical Excellence, 2002 Oct
54. Rose G, Blackburn H. Cardiovascular survey methods. Geneva: World Health Organization, 1968
55. Classificazione delle Malattie, Traumatismi e Cause di Morte. IX Revisione 1975. Roma: Istituto Centrale di Statistica, Metodi e Norme Serie C, N.10, 1984
56. BMDP. Statistical software manual. Cork, Ireland: BMDP, 1992
57. Riscard 2002. Software per la stima del rischio cardiovascolare. Roma: Cardioricerca ed, 2002
58. Menotti A, Lanti M, Puddu PE, et al. The risk functions incorporated in Riscard 2002: a software for the prediction of cardiovascular risk in the general population based on Italian data. Ital Heart J 2002; 3: 114-21
59. CCM: il progretto cuore [online]. Available from URL: http://www.cuore.iss.it [Accessed 2007 Sep 1]
60. Carta del Rischio Cardiovascolare Globale. Progetto Cuore. Istituto Superiore di Sanità, Dicembre 2003 [online]. Available from URL: http://www.cuore.iss.it [Accessed 2007 Sep 1]
61. Giampaoli S, Palmieri L, Chiodini P, et al. La carta del rischio cardiovascolare globale. Ital Heart J Suppl 2004; 5 (3): 177-85
62. Il Progetto Cuore: Studi Longitudinali. Ital Heart J 2004; 5 Suppl. 3: 94S-101S
63. Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apoliproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 325-33
64. Chapman J. Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. Eur Heart J Suppl 2005; Suppl. F: F56-62
65. Barter PH, Rye KA. High density cholesterol: the new target. A handbook for clinicians. Birmingham (UK): Sherborne Gibbs Ltd, 2005
66. Carlson LA. Niaspan: the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 2004; 58: 706-13